In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...
Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham. The Recursion Pharmaceuticals ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Recursion Pharmaceuticals, Inc., a biotechnological firm based in Salt Lake City, Utah, disclosed today that Genentech, Inc. has exercised an option for a Neuroscience Phenomap under a collaboration ...
コンピュータサイエンス学習プラットフォーム「Recursion」を提供するRecursion, Inc（本社：カリフォルニア州ロサンゼルス、共同創業者：田島慎也 、Jeffry Alvarado、以下当社）は、2020年9月8日、初級編に引き続き、「コンピュータサイエンス基礎：中級編」を ...
新卒エンジニアになるためのコンピュータサイエンス学習。Recursionでは、元Metaのエンジニアが作成した800時間分の独自カリキュラムをオンラインで無償提供します。 Recursionは、アメリカの大学のコンピュータサイエンスの課程を参考に元Metaのソフトウェア ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する